Investment Management
Harrold van Barlingen
Harrold, managing partner, headed the life sciences effort of AlpInvest Partners managing a portfolio of over 30 companies, prior to founding Thuja Capital in 2006. Harrold joined AlpInvest Partners in 2001, from the Boston Consulting Group (‘BCG’), where he worked as a consultant in management and strategy. Before BCG, he was acting head of the continental activities of the Lewin Group (a Quintiles subsidiary), an international firm specialized in the field of health economy.
Harrold holds a M.Sc. degree in Medical Biology and a Ph.D. in Medicine, both from Utrecht University. From 1991-1992 he was a visiting scientist at the University of Chicago, USA. He is the author of a wide-variety of peer-reviewed scientific and pharmaco-economics papers.
Harrold serves on the supervisory boards of TheraSolve (chairman), Akeso Medical Imaging (chairman), Okapi Sciences and Galapagos (GLPG, Euronext).
Michel Briejer
Michel, partner, joined Thuja Capital early 2008. He has gained broad hands-on as well as strategic experience in a variety of senior management positions both in the international pharmaceutical industry (e.g. Janssen Pharmaceutica (Belgium), Yamanouchi (currently Astellas Pharma)) as well as in the biotech industry (Crucell). Moreover, he worked as a consultant for a number of small pharmaceutical and biotech start-up companies in The Netherlands.
Michel brings a wealth of drug development know-how to the Thuja team, ranging from small molecules to biotech products. Moreover, having been in charge of various drug development programs as a project leader, he understands the complexity of drug development and project management, and has built a large network of specialists.
Michel holds a M.Sc. degree in Pharmacy (Utrecht University) and a Ph.D. in Pharmacology (Wageningen University), as well as a post-doctoral degree in Pharmaceutical Medicine (Dip.Phar.Med., European Center for Pharmaceutical Sciences, Basle). Michel authored over 25 peer reviewed scientific papers and book chapters on pharmacology and drug development.
Michel is on the supervisory boards of Fabpulous (chairman), NightBalance and DCPrime (chairman).